Treatment with a VEGFR-2 antibody results in intra-tumor immune modulation and enhances anti-tumor efficacy of PD-L1 blockade in syngeneic murine tumor models

作者
Yanxia Li,Nelusha Amaladas,Marguerita O’Mahony,Jason R. Manro,Ivan V. Inigo,Qi Li,Erik Rasmussen,Manisha Brahmachary,Thompson N. Doman,Gerald Hall,Michael D. Kalos,Ruslan D. Novosiadly,Óscar Puig,Bronislaw Pytowski,David Schaer
出处
期刊:PLOS ONE [Public Library of Science]
卷期号:17 (7): e0268244-e0268244 被引量:22
标识
DOI:10.1371/journal.pone.0268244
摘要

Prolonged activation of vascular endothelial growth factor receptor-2 (VEGFR-2) due to mis-regulation of the VEGF pathway induces aberrant blood vessel expansion, which supports growth and survival of solid tumors. Therapeutic interventions that inhibit the VEGFR-2 pathway have therefore become a mainstay of cancer treatment. Non-clinical studies have recently revealed that blockade of angiogenesis can modulate the tumor microenvironment and enhance the efficacy of concurrent immune therapies. Ramucirumab is an FDA-approved anti-angiogenic antibody that inhibits VEGFR-2 and is currently being evaluated in clinical studies in combination with anti-programmed cell death (PD-1) axis checkpoint inhibitors (pembrolizumab, durvalumab, or sintilimab) across several cancer types. The purpose of this study is to establish a mechanistic basis for the enhanced activity observed in the combined blockade of VEGFR-2 and PD-1-axis pathways. Pre-clinical studies were conducted in murine tumor models known to be responsive to anti-PD-1 axis therapy, using monoclonal antibodies that block mouse VEGFR-2 and programmed death-ligand 1 (PD-L1). Combination therapy resulted in enhanced anti-tumor activity compared to anti-PD-L1 monotherapy. VEGFR-2 blockade at early timepoints post-anti-PD-L1 therapy resulted in a dose-dependent and transient enhanced infiltration of T cells, and establishment of immunological memory. VEGFR-2 blockade at later timepoints resulted in enhancement of anti-PD-L1-driven immune cell infiltration. VEGFR-2 and PD-L1 monotherapies induced both unique and overlapping patterns of immune gene expression, and combination therapy resulted in an enhanced immune activation signature. Collectively, these results provide new and actionable insights into the mechanisms by which concurrent VEGFR-2 and PD-L1 antibody therapy leads to enhanced anti-tumor efficacy.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
情怀的应助被科研通管家采纳,获得10
刚刚
NexusExplorer的应助被科研通管家采纳,获得10
刚刚
SciGPT的应助被科研通管家采纳,获得10
刚刚
C.Cat的应助被科研通管家采纳,获得10
1秒前
YYM完成签到 ,获得积分10
1秒前
1秒前
十三月发布了新的文献求助10
2秒前
cherry完成签到,获得积分10
2秒前
int0发布了新的文献求助10
2秒前
nansang发布了新的文献求助10
2秒前
满栀完成签到,获得积分20
3秒前
英俊的铭的应助被吃饭饭采纳,获得10
3秒前
深情安青的应助被yy采纳,获得10
3秒前
qqq完成签到,获得积分10
4秒前
zzz完成签到 ,获得积分10
4秒前
DiNg关注了科研通微信公众号
4秒前
止观发布了新的文献求助10
4秒前
5秒前
5秒前
咯噔发布了新的文献求助20
6秒前
Q甜完成签到,获得积分10
7秒前
锅锅完成签到,获得积分10
7秒前
文艺的白开水完成签到,获得积分10
7秒前
呼呼完成签到 ,获得积分10
7秒前
小马甲的应助被Rxin采纳,获得10
7秒前
7秒前
liu的应助被白英采纳,获得10
7秒前
enen完成签到,获得积分10
7秒前
舒适冬瓜完成签到 ,获得积分10
8秒前
在水一方的应助被笨笨的曼文采纳,获得10
9秒前
9秒前
9秒前
wj完成签到,获得积分10
9秒前
10秒前
wenlongliu完成签到,获得积分10
10秒前
科目三的应助被Cheng采纳,获得10
10秒前
Damin完成签到,获得积分10
11秒前
12秒前
12秒前
Ava的应助被小杨梅采纳,获得10
12秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology)求助 1000
Encyclopedia of Modern Artificial Intelligence 1000
John McDowells Bildungstheorie 800
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
Synthesis, Application and Future Perspectives of Smart Nano-materials - Part 1 400
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8153492
求助须知:如何正确求助?哪些是违规求助? 9550166
关于积分的说明 21696892
捐赠科研通 7742051
什么是DOI,文献DOI怎么找? 3425502
关于科研通互助平台的介绍 2550620
邀请新用户注册赠送积分活动 2469156